Skip to main
  1. Stocks
  2. Amphastar Pharma
  3. Forecast
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 0%
Hold 67%
Sell 17%
Strong Sell 0%

Bulls say

Amphastar Pharma is supported by a strengthening launch pipeline and resilient core demand, with AMP-007 recently approved by the FDA in February 2026 and launched in April 2026, backed by 180 days of generic exclusivity that could make it a $30MM-$40MM sales opportunity. Management’s guidance for 2027 launches of AMP-018 and AMP-004 adds visible future catalysts, while AMP-110 provides longer-term upside in a two-player ACTH category with brisk volume growth. Even with Baqsimi expectations adjusted lower, the company still maintained 2026 high-single digit top-line growth, helped by solid 1Q26 sales in Primatene at $29.8M and epinephrine at $19.2MM, reinforcing a positive fundamental outlook.

Bears say

Amphastar Pharma is under pressure because its flagship Baqsimi franchise is facing persistent pricing erosion from higher rebates, 340B pharmacy discounts, and a less favorable channel mix, with 2Q26 sales of $45.5M down from $46.7M in 2Q25 despite 17% prescription growth. Its core generics business is also weakening, as injectable glucagon fell about 42% in 2Q26 and 56% in 1Q26 after Viatris entered the market in December 2024, while epi­nephrine growth has been modest and partly offset by supplier shortages. Although revenue reached $183.9M in 2Q26 and non-GAAP EPS beat estimates at $0.91, the pipeline remains too uncertain, with limited visibility into when Phase I ACTH or other shots-on-goal can support durable top-line and EBITDA growth.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction

Get the latest Amphastar Pharma (AMPH) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Amphastar Pharma (AMPH)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Oct 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction

Get the latest Amphastar Pharma (AMPH) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Amphastar Pharma (AMPH)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AMPH stock data and trends